DK3062815T3 - Vektorer til ekspression af prostata-associerede antigener - Google Patents

Vektorer til ekspression af prostata-associerede antigener Download PDF

Info

Publication number
DK3062815T3
DK3062815T3 DK14802175.1T DK14802175T DK3062815T3 DK 3062815 T3 DK3062815 T3 DK 3062815T3 DK 14802175 T DK14802175 T DK 14802175T DK 3062815 T3 DK3062815 T3 DK 3062815T3
Authority
DK
Denmark
Prior art keywords
seq
nucleotide sequence
polypeptide
immunogenic
nucleotide
Prior art date
Application number
DK14802175.1T
Other languages
English (en)
Inventor
Joseph John Binder
Helen Kim Cho
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK3062815T3 publication Critical patent/DK3062815T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21077—Semenogelase (3.4.21.77), i.e. prostate specific antigen or PSA or kallikrein 3
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (24)

1. C68-vektor omfattende: (a) en C68-nukleotidsekvens; og (b) et multi-antigen-konstrukt, der omfatter mindst en nukleotidsekvens, der koder for et immunogent cytosolisk PSA-polypeptid, mindst en nukleotidsekvens, der koder for et immunogent PSCA-polypeptid, og mindst en nukleotidsekvens, der koder for et immunogent PSMA-polypeptid, og hvor multi-antigen-konstruktet yderligere omfatter en separatorsekvens mellem to nu-kleotidsekvenser, der koder for to forskellige immunogene polypeptider og har strukturen med formel (I): PAA1-SS1-PAA2-SS2-PAA3 (I) hvor i formel (I): (i) PAA1, PAA2 og PAA3 hver er en nukleotidsekvens, der koder for et immunogent PSA-polypeptid, en nukleotidsekvens, der koder for et immunogent PSCA-polypeptid, eller en nukleotidsekvens, der koder for et immunogent PSMA-polypeptid, forudsat at PAA1, PAA2 og PAA3 koder for forskellige PAA-polypeptider, og (ii) SS1 og SS2 er separatorsekvenser og kan være den samme eller forskellige.
2. C68-vektor ifølge krav 1, hvor C68-nukleotidsekvensen er sekvensen med SEQ ID NO: 57, som mangler mindst et gen udvalgt fra gruppen bestående af E1A-, E1B-, E2A-, E2B-, E3-, E4-, L1-, L2-, L3-, L4- og L5-gener, hvor det immunogene PSA-polypeptid omfatter aminosyre 27-263 med SEQ ID NO:15 eller aminosyre 4 - 240 med SEQ ID NO:17, hvor det immunogene PSCA-polypeptid omfatter aminosyresekvensen med SEQ ID NO:21 eller aminosyre 4-125 med SEQ ID NO:21, og hvor det immunogene PSMA-polypeptid er udvalgt fra gruppen bestående af: 1) et polypeptid omfattende aminosyre 15-750 med SEQ ID NO: 1; 2) et polypeptid omfattende aminosyresekvensen med SEQ ID NO:3; 3) et polypeptid omfattende aminosyresekvensen med SEQ ID NO:5; 4) et polypeptid omfattende aminosyresekvensen med SEQ ID NO:7; 5) et polypeptid omfattende aminosyre 4 - 739 med SEQ ID NO:9; 6) et polypeptid omfattende aminosyre 4 - 739 med SEQ ID NO:3; 7) et polypeptid omfattende aminosyre 4 - 739 med SEQ ID NO:5; 8) et polypeptid omfattende aminosyre 4 - 739 med SEQ ID NO:7; og 9) et polypeptid omfattende aminosyresekvensen med SEQ ID NO: 9.
3. C68-vektor ifølge krav 2, hvor C68-nukleotidsekvensen er sekvensen med SEQ ID NO: 57, som mangler generne E1 A, E1B og E3.
4. C68-vektoren ifølge krav 3, hvor separatorsekvenserne er udvalgt blandt 2A-peptidsekvenser og IRESs.
5. C68-vektor ifølge krav 4, hvor 2A-peptidsekvensen er udvalgt fra gruppen bestående af 2A-peptidsekvensen med FMDV, ERAV, PTV1, EMC-B, EMCV, TME-GD7, ERBV, TaV, DrosC, CrPV, ABPV, IFV, svine-rotavirus, human rotavirus, T brucei TSR1 og T cruzi AP-endonuklease; og hvor IRES'et er et EMCV-IRES.
6. Vektor ifølge krav 5, hvor PAA1 i formel (I) er en nukleotidsekvens, der koder for det immunogene cytosoliske PSA-polypeptid, eller en nukleotidsekvens, der koder for det immunogene PSCA-polypeptid.
7. Vektor ifølge krav 6, hvor: (i) PAA1 er en nukleotidsekvens, der koder for det immunogene cytosoliske PSA-polypeptid; (ii) PAA2 er en nukleotidsekvens, der koder for et immunogent PSCA eller PSMA-polypeptid; (iii) SS1 er en 2A-peptidsekvens; og (iv) SS2 er en 2A-peptidsekvens eller en EMCV-IRES.
8. C68-vektor ifølge krav 7, hvor 2A-peptidsekvensen er FMDV 2A-peptidse-kvensen eller TAV 2A-peptidsekvensen.
9. C68-vektor ifølge krav 8, hvor: (1) nukleotidsekvensen, der koder for det immunogene cytosoliske PSA-polypeptid, er udvalgt fra gruppen bestående af: (i) nukleotidsekvensen med SEQ ID NO: 18; (ii) nukleotidsekvensen omfattende nukleotid 10-720 med SEQ ID N0:18; (iii) nukleotidsekvensen omfattende nukleotid 1115-1825 med SEQ ID NO:58; og (iv) nukleotidsekvensen omfattende nukleotid 1106-1825 med SEQ ID NO:58; (2) nukleotidsekvensen, der koder for det immunogene PSCA-polypeptid, er udvalgt fra gruppen bestående af: (i) nukleotidsekvensen med SEQ ID NO:22; (ii) en nukleotidsekvens omfattende nukleotid 10-372 med SEQ ID NO:22; (iii) en nukleotidsekvens omfattende nukleotid 1892-2257 med SEQ ID NO:58; og (iv) en nukleotidsekvens omfattende nukleotid 1886-2257 med SEQ ID NO:58; og (3) nukleotidsekvensen, der koder for det immunogene PSMA-polypeptid, er udvalgt fra gruppen bestående af: (i) nukleotidsekvensen omfattende nukleotid 43-2250 med SEQ ID NO:2; (ii) nukleotidsekvensen med SEQ ID NO:4; (iii) nukleotidsekvensen med SEQ ID NO:6; (iv) nukleotidsekvensen med SEQ ID NO:8; (v) nukleotidsekvensen med SEQ ID NO:10; (vi) en nukleotidsekvens omfattende nukleotid 10 - 2217 med SEQ ID NO:4; (vii) en nukleotidsekvens omfattende nukleotid 10 - 2217 med SEQ ID NO:6; (viii) en nukleotidsekvens omfattende nukleotid 10 - 2217 med SEQ ID NO:8; (ix) en nukleotidsekvens omfattende nukleotid 10 - 2217 med SEQ ID NO:10; (x) en nukleotidsekvens omfattende nukleotid 2333-4543 med SEQ ID NO:58; og (xi) en nukleotidsekvens omfattende nukleotid 2324-4543 med SEQ ID NO:58.
10. C68-vektor ifølge krav 3, hvor, i formel (I): (1) PAA1 er en nukleotidsekvens, der koder for en immunogen cytosolisk PSA-polypeptid og omfatter nukleotid 1115-1825 med SEQ ID NO: 58; (2) PAA2 er en nukleotidsekvens, der koder for et immunogent PSCA-polypeptid og omfatter nukleotid 1892-2257 med SEQ ID NO: 58 eller omfatter 1886-2257 med SEQ ID NO: 58; (3) PAA3 er en nukleotidsekvens, der koder for et immunogent PSMA-polypeptid og omfatter nukleotid 2333-4543 med SEQ ID NO: 58 eller omfatter 2324-4543 med SEQ ID NO: 58; (4) SS1 er en nukleotidsekvens, der koder for T2A; og (5) SS2 er en nukleotidsekvens, der koder for F2A.
11. C68-vektor ifølge krav 1, hvor multi-antigen-konstruktet omfatter en nukleotidsekvens, der koder for aminosyresekvensen med SEQ ID NQ:60 eller SEQ ID NO:64.
12. C68-vektor ifølge krav 1, hvor multi-antigen-konstruktet omfatter en nukleotidsekvens med SEQ ID NO:61, SEQ ID NO:65, SEQ ID NO:66 eller en degenereret variant af nukleotidsekvensen med SEQ ID NO:61, SEQ ID NO:65, SEQ ID NO:66.
13. C68-vektor ifølge krav 11 eller krav 12, yderligere omfattende en CMV-promoter.
14. C68-vektor ifølge krav 1, som omfatter nukleotidsekvensen med SEQ ID NO:58, nukleotid 9-34811 med SEQ ID NO:58 eller nukleotidsekvensen med SEQ ID NO:63.
15. Sammensætning omfattende en C68-vektor ifølge et hvilket som helst af kravene 1-14.
16. Celle omfattende en C68-vektor ifølge et hvilket som helst af kravene 1-14.
17. Farmaceutisk sammensætning omfattende en vektor ifølge et hvilket som helst af kravene 1-14 og en farmaceutisk acceptabel excipiens.
18. Farmaceutisk sammensætning ifølge krav 17 til anvendelse i en fremgangsmåde til behandling af prostatacancer hos et menneske.
19. Farmaceutisk sammensætning til anvendelse ifølge krav 18, hvor fremgangsmåden yderligere omfatter indgivelse til mennesket af en virksom mængde af en immunmodulator.
20. Farmaceutisk sammensætning til anvendelse ifølge krav 18, hvor fremgangsmåden yderligere omfatter indgivelse til mennesket af (a) en virksom mængde af mindst en inhibitor af immunsuppressive celler og (b) en virksom mængde af mindst en enhancer af immuneffektorceller.
21. Farmaceutisk sammensætning til anvendelse ifølge krav 20, hvor inhibitoren af immunsuppressive celler er udvalgt fra gruppen bestående af en prote-inkinase-inhibitor, en COX-2-inhibitor og en PDE5-inhibitor, og hvor enhance-ren af immuneffektorceller er udvalgt fra gruppen bestående af en CTLA-4-inhibitor, en CD40-agonist, en TLR-agonist, en 4-1 BB-agonist, en OX40-ago-nist, en GITR-agonist, en PD-1-antagonist og en PD-L1-antagonist.
22. Farmaceutisk sammensætning til anvendelse ifølge krav 21, hvor: (1) proteinkinase-inhibitoren er udvalgt fra gruppen bestående af imatinib, sorafenib, lapatinib, zactima MP-412, dasatinib, lestaurtinib, sunitinibmalat, axitinib, erlotinib, gefitinib, bosutinib, temsirolismus og nilotinib; (2) CTLA-4-inhibitoren er udvalgt fra gruppen bestående af ipilimumab og tre-melimumab; (3) CD40-agonisten er et anti-CD40-antistof udvalgt fra gruppen bestående af G28-5, mAb89, EA-5, S2C6, CP870893 og dacetuzumab; og (4) TLR-agonisten er et CpG-oligonukleotid udvalgt fra gruppen bestående af CpG 24555, CpG 10103, CpG7909 og CpG1018.
23. Farmaceutisk sammensætning til anvendelse ifølge krav 22, hvor inhibitoren af immunsuppressive celler er en proteinkinase-inhibitor udvalgt fra gruppen bestående af sorafenib, dasatinib, imatinib, axitinib og sunitinibmalat, og hvor enhanceren af immuneffektorceller er tremelimumab.
24. Farmaceutisk sammensætning til anvendelse ifølge krav 22, hvor inhibitoren af immunsuppressive celler er en proteinkinase-inhibitor udvalgt fra gruppen bestående af sorafenib, dasatinib, imatinib, axitinib og sunitinibmalat, og hvor enhanceren af immuneffektorceller er et CpG-oligonukleotid udvalgt fra gruppen bestående af CpG24555, CpG10103, CpG7909 og CpG1018.
DK14802175.1T 2013-11-01 2014-10-17 Vektorer til ekspression af prostata-associerede antigener DK3062815T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361898966P 2013-11-01 2013-11-01
PCT/IB2014/065419 WO2015063647A1 (en) 2013-11-01 2014-10-17 Vectors for expression of prostate-associated antigens

Publications (1)

Publication Number Publication Date
DK3062815T3 true DK3062815T3 (da) 2019-03-11

Family

ID=51945953

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14802175.1T DK3062815T3 (da) 2013-11-01 2014-10-17 Vektorer til ekspression af prostata-associerede antigener

Country Status (27)

Country Link
US (3) US9402901B2 (da)
EP (2) EP3524262A1 (da)
JP (3) JP2016535989A (da)
KR (2) KR102196884B1 (da)
CN (1) CN105682679B (da)
AR (2) AR098256A1 (da)
AU (2) AU2014343321B2 (da)
BR (1) BR112016008806A2 (da)
CA (1) CA2928908C (da)
DK (1) DK3062815T3 (da)
ES (1) ES2715890T3 (da)
HU (1) HUE043042T2 (da)
IL (1) IL244897A0 (da)
MX (2) MX2016005656A (da)
MY (2) MY182168A (da)
NZ (1) NZ718652A (da)
PE (1) PE20171142A1 (da)
PH (2) PH12016500673A1 (da)
PL (1) PL3062815T3 (da)
PT (1) PT3062815T (da)
RU (2) RU2018108259A (da)
SA (1) SA516371030B1 (da)
SG (2) SG10201910889VA (da)
SI (1) SI3062815T1 (da)
TR (1) TR201903074T4 (da)
TW (2) TWI572717B (da)
WO (1) WO2015063647A1 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3062815T3 (pl) 2013-11-01 2019-07-31 Pfizer Inc. Wektory do ekspresji antygenów związanych z gruczołem krokowym
US9364523B2 (en) 2014-03-17 2016-06-14 Tapimmune Inc. Chimeric nucleic acid molecule with non-AUG translation initiation sequences
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
CN108289892B (zh) * 2015-06-29 2021-11-23 维瑞斯特姆股份有限公司 治疗组合物、组合和使用方法
IL259931B2 (en) 2015-12-16 2024-02-01 Gritstone Bio Inc Identification of neo-antigens, preparation, and use
CA2954892A1 (en) 2016-01-19 2017-07-19 Pfizer Inc. Immunogens derived from tumor-associated antigens or nucleic acid molecules encoding the immunogens
WO2017129723A1 (en) * 2016-01-27 2017-08-03 Total Raffinage Chimie Multigene expression in microalgae
US20210198689A1 (en) * 2016-03-18 2021-07-01 Nant Holdings Ip, Llc Multimodal Vector for Dendritic Cell Infection
CA3023022A1 (en) * 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
CA3026342A1 (en) * 2016-06-03 2017-12-07 Etubics Corporation Compositions and methods for tumor vaccination using prostate cancer-associated antigens
GB2549809C (en) 2016-06-23 2022-11-30 Univ Oxford Innovation Ltd Vector
US20190328869A1 (en) * 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
MA46904A (fr) * 2016-11-23 2019-10-02 Gritstone Oncology Inc Administration virale de néo-antigènes
WO2018170238A2 (en) * 2017-03-15 2018-09-20 Novavax, Inc. Methods and compositions for inducing immune responses against clostridium difficile
WO2018208856A1 (en) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
RU2020100072A (ru) 2017-07-11 2021-08-11 Пфайзер Инк. Иммуногенные композиции, содержащие cea, muc1 и tert
AU2018348165A1 (en) 2017-10-10 2020-05-21 Gritstone Bio, Inc. Neoantigen identification using hotspots
KR20200090855A (ko) 2017-11-22 2020-07-29 그릿스톤 온콜로지, 인코포레이티드 신생항원에 대한 접합 에피토프 제시 감소
KR20200118029A (ko) 2018-01-04 2020-10-14 아이코닉 테라퓨틱스, 인코포레이티드 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법
TW202110870A (zh) * 2019-05-30 2021-03-16 美商葛利史東腫瘤科技公司 經修飾之腺病毒
RU2726541C1 (ru) * 2019-11-19 2020-07-14 Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) Рекомбинантная клеточная линия рака молочной железы человека BrCCh4e-134, экспрессирующая простат-специфический мембранный антиген человека
CN113088530A (zh) * 2020-01-08 2021-07-09 怡道生物科技(苏州)有限公司 一种基于黑猩猩ChAd63型腺病毒的表达载体及其构建方法
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US628371A (en) 1898-09-10 1899-07-04 Clark W Thomas Machine for making berry-boxes.
JPS58130841A (ja) * 1982-01-29 1983-08-04 Nec Corp 発光マ−ク検知装置
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6083716A (en) 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
JP2001513776A (ja) 1997-02-28 2001-09-04 ユニバーシティ オブ アイオワ リサーチ ファウンデーション ＬＰＳ関連障害の処置における非メチル化ＣｐＧジヌクレオチドを含む核酸の使用
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
CA2291483C (en) 1997-06-06 2012-09-18 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
WO1999011241A1 (en) 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
ES2340745T3 (es) 1998-12-23 2010-06-08 Pfizer Inc. Anticuerpos monoclonales humanos contra ctla-4.
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
EP1159429A2 (en) 1999-02-18 2001-12-05 Compugen Ltd. Psa and klk-2 splicing variants
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
AU6934600A (en) 1999-08-27 2001-03-26 Board Of Regents, The University Of Texas System Cd40 ligand and cd40 agonist compositions and methods of use
WO2001060814A2 (en) 2000-02-15 2001-08-23 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
DE60142615D1 (de) * 2000-04-28 2010-09-02 Mannkind Corp Epitop-synchronisierung in antigen präsentierenden zellen
RU2192889C1 (ru) * 2001-03-16 2002-11-20 Эпштейн Олег Ильич Лекарственное средство и способ лечения заболеваний предстательной железы
EP2305699B1 (de) 2001-06-05 2014-08-13 CureVac GmbH Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Impfung gegen Schlafkrankheit, Leishmaniose und Toxoplasmose
ES2375557T3 (es) 2001-06-22 2012-03-02 The Trustees Of The University Of Pennsylvania Adenovirus recombinantes que comprenden prote�?nas de adenovirus de simios y usos de los mismos.
US20040241181A1 (en) 2001-06-22 2004-12-02 Ertl Hildeghund C. J. Methods of inducing a cytotoxic immune response and recormbinant simian adenovirus compositions useful therein
EP2412242A3 (en) * 2001-07-05 2012-06-13 Novartis Vaccines and Diagnostics, Inc. Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
WO2003004657A1 (en) 2001-07-05 2003-01-16 Chiron Corporation Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
CA2455050C (en) 2001-08-15 2007-02-20 Pharmacia & Upjohn Company Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
WO2003031569A2 (en) * 2001-10-10 2003-04-17 Centocor, Inc. Nucleic acid vaccines using tumor antigen encoding nucleic acids with cytokine adjuvant encoding nucleic acid
TWI228718B (en) 2001-11-05 2005-03-01 Tdk Corp Manufacturing method and device of mold plate for information medium
SG2013034475A (en) * 2001-11-21 2016-10-28 Univ Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
CN1308326C (zh) 2002-02-15 2007-04-04 法马西亚和厄普乔恩公司 吲哚满酮衍生物的制备方法
TW200418836A (en) 2002-09-10 2004-10-01 Pharmacia Italia Spa Formulations comprising an indolinone compound
CA2514419A1 (en) 2003-01-28 2004-08-12 Proscan Rx Pharma Inc. Prostate cancer diagnosis and treatment
SI1629088T1 (sl) * 2003-05-30 2012-08-31 Agensys Inc Antigen izvornih celic prostate (psca) in njegova podzaporedja
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
WO2005023765A1 (en) 2003-09-11 2005-03-17 Pharmacia & Upjohn Company Llc Method for catalyzing amidation reactions by the presence of co2
GB0321615D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
CA2553541C (en) * 2004-01-23 2015-04-21 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Chimpanzee adenovirus vaccine carriers
ES2361000T3 (es) 2004-04-28 2011-06-13 The Trustees Of The University Of Pennsylvania Suministro secuencial de moléculas inmunogénicas mediante administraciones de un adenovirus y de un virus adeno-asociado.
DE102004035227A1 (de) 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
ES2525545T3 (es) 2005-09-19 2014-12-26 Janssen Diagnostics, Llc Métodos y usos para identificar el origen de un carcinoma de origen primario desconocido
EP1954311A4 (en) 2005-12-07 2009-12-23 Medarex Inc CTLA-4 ANTIBODY DOSAGE ESCALATION THERAPY
JP5889514B2 (ja) 2006-04-28 2016-03-22 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 改変アデノウイルスヘキソンタンパク質およびその用途
GB0706914D0 (en) 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
WO2009046739A1 (en) * 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
EP2207564B1 (en) 2007-10-18 2016-10-05 Bavarian Nordic A/S Use of mva to treat prostate cancer
JP2013504599A (ja) * 2009-09-14 2013-02-07 ベイラー リサーチ インスティテュート ランゲルハンス細胞に向けられたワクチン
ES2718846T3 (es) * 2010-11-12 2019-07-04 Univ Pennsylvania Antígenos de próstata consenso, molécula de ácido nucleico que los codifica y la vacuna y usos que los comprenden
WO2012116714A1 (en) * 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
EP2694099B1 (en) * 2011-04-08 2019-10-16 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN102294025B (zh) * 2011-08-10 2013-06-05 中国人民解放军第三军医大学第三附属医院 前列腺干细胞抗原多肽与核酸的复合物及其制备方法和应用
PE20142406A1 (es) * 2012-05-04 2015-01-23 Pfizer Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
PL3062815T3 (pl) 2013-11-01 2019-07-31 Pfizer Inc. Wektory do ekspresji antygenów związanych z gruczołem krokowym

Also Published As

Publication number Publication date
AR098256A1 (es) 2016-05-18
RU2018108259A3 (da) 2021-07-05
RU2018108259A (ru) 2019-02-25
KR102006527B1 (ko) 2019-08-02
AR118725A2 (es) 2021-10-27
CA2928908C (en) 2021-01-12
PL3062815T3 (pl) 2019-07-31
SA516371030B1 (ar) 2021-01-20
PE20171142A1 (es) 2017-08-10
AU2014343321A1 (en) 2016-04-28
TW201716579A (zh) 2017-05-16
IL244897A0 (en) 2016-05-31
JP2016535989A (ja) 2016-11-24
JP6621560B2 (ja) 2019-12-18
US9402901B2 (en) 2016-08-02
TR201903074T4 (tr) 2019-03-21
BR112016008806A2 (pt) 2017-10-03
PH12020551666A1 (en) 2021-05-10
HUE043042T2 (hu) 2019-07-29
KR20160068974A (ko) 2016-06-15
AU2014343321B2 (en) 2020-02-06
KR102196884B1 (ko) 2020-12-30
JP7014764B2 (ja) 2022-02-01
MX2016005656A (es) 2016-07-14
JP2019205443A (ja) 2019-12-05
WO2015063647A1 (en) 2015-05-07
EP3524262A1 (en) 2019-08-14
RU2016114416A (ru) 2017-12-06
MX2020001813A (es) 2020-07-13
TWI572717B (zh) 2017-03-01
JP2020096588A (ja) 2020-06-25
EP3062815B1 (en) 2019-01-16
TW201529852A (zh) 2015-08-01
PH12016500673B1 (en) 2016-05-30
AU2020202114A1 (en) 2020-04-16
PT3062815T (pt) 2019-03-27
US20160235829A1 (en) 2016-08-18
TWI650418B (zh) 2019-02-11
RU2650860C2 (ru) 2018-04-17
SG11201602625YA (en) 2016-05-30
KR20190090885A (ko) 2019-08-02
MY196581A (en) 2023-04-19
MY182168A (en) 2021-01-18
SG10201910889VA (en) 2020-01-30
US20150125465A1 (en) 2015-05-07
US20180369352A1 (en) 2018-12-27
PH12016500673A1 (en) 2016-05-30
US11173196B2 (en) 2021-11-16
EP3062815A1 (en) 2016-09-07
CN105682679A (zh) 2016-06-15
CN105682679B (zh) 2020-12-08
CA2928908A1 (en) 2015-05-07
NZ718652A (en) 2019-06-28
US10092636B2 (en) 2018-10-09
SI3062815T1 (sl) 2019-05-31
ES2715890T3 (es) 2019-06-06

Similar Documents

Publication Publication Date Title
DK3062815T3 (da) Vektorer til ekspression af prostata-associerede antigener
KR101728483B1 (ko) 전립선 관련된 항원 및 백신 기재 면역치료 요법
AU2020260485B2 (en) Gene therapies for lysosomal disorders
AU2015263150B2 (en) Lentiviral vectors
ES2388527T3 (es) Vacunas de VIH basadas en Env de múltiples clados de VIH
RU2758489C2 (ru) Композиции и способы для экспрессии нескольких биологически активных полипептидов с одного вектора для лечения заболеваний сердца и других патологий
DK2753355T3 (da) Onkolytisk herpes simplex virus og terapeutiske anvendelser deraf
AU2020344628A1 (en) Compositions and methods for TCR reprogramming using fusion proteins
KR20210150486A (ko) 리소좀 장애에 대한 유전자 요법
CN111065408A (zh) 免疫原性组合物
KR20230066360A (ko) 신경퇴행성 장애를 위한 유전자 요법
KR20210150487A (ko) 리소좀 장애를 위한 유전자 요법
TW202233830A (zh) 使用下一代工程化t細胞療法治療癌症之組合物及方法